Kenvue Inc. (KVUE) is a consumer health company valued at $33.5 billion, based in Summit, New Jersey. Despite lagging behind the market, shares have declined 18.4% over the past 52 weeks. On Nov. 3, shares rose 12.3% after Kimberly-Clark Corporation announced a $48.7 billion acquisition deal.

Analysts expect KVUE’s EPS to decline 9.7% this fiscal year, but the company has consistently met or topped consensus estimates in the last four quarters. The consensus rating among 12 analysts is “Hold,” with a “Moderate Buy” overall rating. Nik Modi from RBC Capital maintains a “Hold” rating with a $21 price target.

The mean price target of $19 represents an 8.6% premium from current levels, while the Street-high target of $23 suggests a 31.4% potential upside. The company’s configuration has shifted from bullish to “Moderate Buy” in the last three months. This information is solely for informational purposes and was originally published on Barchart.com.

Read more at Yahoo Finance: Kenvue Stock: Analyst Estimates & Ratings